Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Apr
15
2024
Chlormequat Contamination in Food Products Draws Attention K&L Gates
Apr
12
2024
ARS Researchers Discover Ability of Cotton Gin Waste to Transform Silver Ions into Silver Nanoparticles Bergeson & Campbell, P.C.
Apr
12
2024
McDermottPlus Check-Up: April 12, 2024 McDermott Will & Emery
Apr
12
2024
340B Remedy Rule and Medicare Advantage Rates: Navigating Shifting Payments McDermott Will & Emery
Apr
11
2024
FDA Releases Draft Guidance on New Dietary Ingredient Notification Master Files for Dietary Supplements Epstein Becker & Green, P.C.
Apr
11
2024
ITU Applicants Beware: Federal Courts Have Jurisdiction Over Pending Trademark Applications McDermott Will & Emery
Apr
11
2024
Kratom Chronicles: Maryland Steps Up Herbal Saga, Other States Leafing Through Their Laws Norris McLaughlin P.A.
Apr
11
2024
China Semiconductor Export Regulations, Episode V – Updates and Corrections to the Advanced Computing and Semiconductor Regulations Sheppard, Mullin, Richter & Hampton LLP
Apr
10
2024
Floridians to Decide Fate of Adult-Use Marijuana This November Bradley Arant Boult Cummings LLP
Apr
9
2024
This Week in 340B: April 2 – April 8, 2024 McDermott Will & Emery
Apr
9
2024
FDA Reports That No Asbestos Was Detected in Its 2023 Testing of Talc-Containing Cosmetic Products Bergeson & Campbell, P.C.
Apr
9
2024
PBM Policy and Legislative Update — Winter 2024 Mintz
Apr
9
2024
California Greatly Expands List of Cosmetics Fragrances Reportable as Allergens ArentFox Schiff LLP
Apr
9
2024
The Italian DPA Has Its Eyes on Biometric IDs – Another Fight on Tech or a Win for Privacy? Squire Patton Boggs (US) LLP
Apr
8
2024
FDA Publishes Draft Guidance on NDIN Master Files Keller and Heckman LLP
Apr
8
2024
Will Hemp Save the World, Before the Government Kills It? Bradley Arant Boult Cummings LLP
Apr
8
2024
While You Were Sleeping – Development of the Hydrogen Hubs Keeps On Rolling Barnes & Thornburg LLP
Apr
6
2024
EPA Proposes to Require Submission of Health and Safety Studies for 16 Chemicals Being Considered for TSCA Risk Evaluation Bergeson & Campbell, P.C.
Apr
5
2024
Pharmaceutical Companies May Be the First Targets of the Washington State My Health My Data Act Greenberg Traurig, LLP
Apr
5
2024
New York Cannabis Regulations Are (Initially Ruled) Unconstitutional, Says New York Judge ArentFox Schiff LLP
Apr
4
2024
Proposal to Revamp Alabama Medical Cannabis Program Met with Near-Unanimous Opposition Bradley Arant Boult Cummings LLP
Apr
4
2024
Cancer Drugs (Antibody Drug Conjugates): An FDA Perspective Foley & Lardner LLP
Apr
4
2024
FDA Reminds Stakeholders of Animal Drug ‘Approved by FDA’ Labeling Requirements Greenberg Traurig, LLP
Apr
4
2024
Take the Beer Goggles Off: Ambiguity Prevents Summary Judgment McDermott Will & Emery
Apr
4
2024
CTP Releases New 5-year Strategic Plan Keller and Heckman LLP
Apr
4
2024
AMS Requests Information to Update List of Bioengineered Foods Bergeson & Campbell, P.C.
Apr
3
2024
FTC’s Campaign Against Improper Orange Book Listings Continues with Amicus Brief in Teva’s Challenge of Amneal Asthma Inhaler ANDA Sheppard, Mullin, Richter & Hampton LLP
Apr
3
2024
EPA Describes Future of Its Nanotechnology Research Bergeson & Campbell, P.C.
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins